by Marybeth Burke – Initial combination chemotherapy with bendamustine and rituximab more than doubled progression-free survival to nearly 6 years compared with standard R-CHOP therapy among patients with… read more.
by Marybeth Burke – Adding bevacizumab to chemotherapy halves the risk of the disease getting worse in platinum resistant patients with ovarian cancer,
by Marybeth Burke – Crizotinib demonstrated significant anti-tumour activity in patients with advanced non-small cell lung cancer (NSCLC) harbouring ROS1 rearrangements,
by Marybeth Burke – Women treated for childhood cancer with chest radiation therapy have a high risk of developing breast cancer at a young age, comparable to that… read more.
by Marybeth Burke – Regorafenib significantly improved progression-free survival (PFS) and disease control rate (DCR) in patients with advanced gastrointestinal stromal tumours (GIST) that progress due to resistance… read more.
by Marybeth Burke – The investigational agent trastuzumab emtansine (T-DM1) demonstrated improved efficacy over capecitibine plus lapatinib and improved progression-free survival (PFS) in women with HER2-positive locally advanced… read more.
by Marybeth Burke – Median progression-free survival (PFS) was significantly greater in the trametinib group, 4.8 months, vs the chemotherapy group, 1.4 months, according to a study presented
by Marybeth Burke – Wisconsin grown ginseng significantly reduced cancer related fatigue in patients receiving cancer treatment after 8 weeks of ginseng treatment,
by Marybeth Burke – Continuous hormonal therapy is more effective than intermittent hormonal therapy for men with hormone-sensitive metastatic prostate cancer with minimal disease spread,
by Marybeth Burke – Some of the most essential mainstays in cancer treatment drugs for adults and children are in short supply, Michael Link, M.D., president of the… read more.
by Marybeth Burke – The investigational drug BMS-936558 caused tumour shrinkage in up to a quarter of patients with advanced melanoma, kidney and NSCLC cancers,
by Marybeth Burke – Afatinib, an irreversible ErbB-family blocker, delays progression of advanced lung cancer in patients with epidermal growth factor receptor (EGFR) mutations compared with standard chemotherapy,
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
